InterventionsHumans

Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease

Figure 1 from Advances in Therapy
Open the figure at full size
Figure 1Amamoo et al.

Advances in Therapy

The paper

Novo Nordisk (United States) · University of Maryland, Baltimore

Advances in Therapy · 23 Sep 2026

doi.org/10.1007/s12325-026-03744-8PubMed 42776473

More on GLP-1 and incretin signalling